CND Life Sciences Implements Syn-One Biomarker Services in Innovative Phase 2 Parkinson's Disease Trial CND Life Sciences' Syn-One® services measure alpha-synuclein in Parkinson’s research, showcasing potential for drug development in clinical trials.

CND Life Sciences Implements Syn-One Biomarker Services in Innovative Phase 2 Parkinson's Disease Trial #United_States #Scottsdale #Parkinson's_Disease #CND_Life_Sciences #Syn-One

CND Life Sciences Marks a Milestone with 50,000th Syn-One Test® Using Skin Biopsy Technology CND Life Sciences celebrates the completion of its 50,000th Syn-One Test, a breakthrough in diagnosing synucleinopathies, enhancing patient care nationwide.

CND Life Sciences Marks a Milestone with 50,000th Syn-One Test® Using Skin Biopsy Technology #USA #Scottsdale #CND_Life_Sciences #Syn-One_Test #Neurodiagnostics

CND Life Sciences Secures NIH Grant to Assess Parkinson's Risk in Essential Tremor Patients CND Life Sciences has been awarded a $3 million NIH grant to explore the link between essential tremor and the risk of Parkinson's disease. Their groundbreaking study examines biomarkers in patients to enhance early intervention approaches.

CND Life Sciences Secures NIH Grant to Assess Parkinson's Risk in Essential Tremor Patients #United_States #Scottsdale #Parkinson's_Disease #CND_Life_Sciences #Essential_Tremor

CND Life Sciences Achieves FDA Breakthrough Device Designation for Syn-One Test® CND Life Sciences has received the FDA's Breakthrough Device Designation for its Syn-One Test, aiding in the diagnosis of synucleinopathies in patients.

CND Life Sciences Achieves FDA Breakthrough Device Designation for Syn-One Test® #USA #Scottsdale #CND_Life_Sciences #Syn-One_Test #FDA_Breakthrough

CND Life Sciences' Innovative Syn-One Test: A Breakthrough for REM Sleep Behavior Disorder Diagnosis CND Life Sciences unveiled promising results from their Syn-One Test, detecting alpha-synuclein in skin biopsies of patients with REM sleep behavior disorder, highlighting its potential as a diagnostic tool.

CND Life Sciences' Innovative Syn-One Test: A Breakthrough for REM Sleep Behavior Disorder Diagnosis #United_States #Scottsdale #CND_Life_Sciences #Syn-One_Test #Alpha-Synuclein

CND Life Sciences Secures $13.5M Series A Funding for Neurodiagnostic Innovations CND Life Sciences announces successful $13.5 million Series A equity round, aiming to enhance neurodiagnostics and patient care.

CND Life Sciences Secures $13.5M Series A Funding for Neurodiagnostic Innovations #United_States #Scottsdale #CND_Life_Sciences #Syn-One_Test #Neurodiagnostics

CND Life Sciences to Showcase Pioneering Skin Biopsy Diagnostic Innovations for Dementia at AAN 2025 CND Life Sciences will present three pivotal clinical trial updates on their skin biopsy tool for dementia diagnostics at the upcoming AAN 2025.

CND Life Sciences to Showcase Pioneering Skin Biopsy Diagnostic Innovations for Dementia at AAN 2025 #United_States #San_Diego #CND_Life_Sciences #Dementia_Diagnosis #Skin_Biopsy_Tool

CND Life Sciences Reveals Groundbreaking Test for Neurodegenerative Disease Diagnosis CND Life Sciences published a study demonstrating the Syn-One Test's effectiveness in diagnosing neurodegenerative diseases accurately.

CND Life Sciences Reveals Groundbreaking Test for Neurodegenerative Disease Diagnosis #USA #Scottsdale #Neurodegenerative_Diseases #CND_Life_Sciences #Syn-One_Test